Enlivex Therapeutics Ltd. - Ordinary Shares (NQ:ENLV)

0.8191 +0.0377 (+4.82%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 6, 2026 Add to My Watchlist

Price and Volume

Volume	259,913
Open	0.7998
Bid (Size)	0.7501 (500)
Ask (Size)	0.8200 (900)
Prev. Close	0.7814
Today's Range	0.7600 - 0.8215
52wk Range	0.6600 - 2.100
Shares Outstanding	18,306,186
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development

December 04, 2025

From Enlivex Therapeutics Ltd

Via GlobeNewswire

Enlivex Announces Closing of Previously Announced $212,000,000 Private Placement

November 26, 2025

From Enlivex Therapeutics Ltd

Via GlobeNewswire

Performance

YTD	+8.5%	+8.5%
1 Month	-25.5%	-25.5%
3 Month	-28.5%	-28.5%
6 Month	-32.3%	-32.3%
1 Year	-33.4%	-33.4%

More News

Kartoon Studios Mainframe Studios, Toon Media, and Premium IP Pipeline Drive 2026-2027 Outlook

November 24, 2025

Via AB Newswire

Which stocks are experiencing notable movement on Monday? ↗

November 24, 2025

Via Chartmill

These stocks are making the most noise in today's session. ↗

November 24, 2025

Via Chartmill

Top movers in Monday's session ↗

November 24, 2025

Via Chartmill

The market is filled with gapping stocks in Monday's session. ↗

November 24, 2025

Via Chartmill

ENLV Stock Surges After Pivot To Crypto-Backed Treasury, Names Former Italian PM To Board ↗

November 24, 2025

Via Stocktwits

Wondering what's happening in today's pre-market session? ↗

November 24, 2025

Via Chartmill

Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

November 24, 2025

From Enlivex Therapeutics Ltd

Via GlobeNewswire

Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis

November 24, 2025

From Enlivex Therapeutics Ltd

Via GlobeNewswire

Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025

October 28, 2025

From Enlivex Therapeutics Ltd

Via GlobeNewswire

Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

October 03, 2025

Via ACCESS Newswire

D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

September 29, 2025

From Enlivex Therapeutics Ltd

Via GlobeNewswire

Enlivex Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

September 19, 2025

Via ACCESS Newswire

Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results

September 11, 2025

From Enlivex Therapeutics Ltd

Via GlobeNewswire

Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

September 09, 2025

From Enlivex Therapeutics Ltd

Via GlobeNewswire

What's going on in today's session ↗

August 18, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

August 18, 2025

Via Benzinga

Monday's session: top gainers and losers ↗

August 18, 2025

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

August 18, 2025

Via Chartmill

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

August 18, 2025

From Enlivex Therapeutics Ltd

Via GlobeNewswire

Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar

August 14, 2025

From Enlivex Therapeutics Ltd

Via GlobeNewswire

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

July 28, 2025

From Enlivex Therapeutics Ltd

Via GlobeNewswire

Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

June 13, 2025

Via ACCESS Newswire

Frequently Asked Questions

Is Enlivex Therapeutics Ltd. - Ordinary Shares publicly traded?

Yes, Enlivex Therapeutics Ltd. - Ordinary Shares is publicly traded.

What exchange does Enlivex Therapeutics Ltd. - Ordinary Shares trade on?

Enlivex Therapeutics Ltd. - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Enlivex Therapeutics Ltd. - Ordinary Shares?

The ticker symbol for Enlivex Therapeutics Ltd. - Ordinary Shares is ENLV on the Nasdaq Stock Market

What is the current price of Enlivex Therapeutics Ltd. - Ordinary Shares?

The current price of Enlivex Therapeutics Ltd. - Ordinary Shares is 0.8191

When was Enlivex Therapeutics Ltd. - Ordinary Shares last traded?

The last trade of Enlivex Therapeutics Ltd. - Ordinary Shares was at 01/06/26 04:00 PM ET

What is the market capitalization of Enlivex Therapeutics Ltd. - Ordinary Shares?

The market capitalization of Enlivex Therapeutics Ltd. - Ordinary Shares is 14.99M

How many shares of Enlivex Therapeutics Ltd. - Ordinary Shares are outstanding?

Enlivex Therapeutics Ltd. - Ordinary Shares has 15M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.